Kintara Therapeutics Inc (KTRA) Stock
KTRA is no longer traded. Kintara Therapeutics was delisted from the Nasdaq in October 2024.
Prices on this page are historical; the last trade was October 18, 2024 at $6.30.
Kintara Therapeutics stock price history
KTRA final trading statistics
- Final close
- $6.30
- Final trading day
- Oct 18, 2024
- Market cap at delisting
- $11.99M
- Shares outstanding
- 55.66M
- Final 52-week range
- $0.08 – $7.93
- Avg. volume (final 3 mo.)
- 334,953
- All-time high (split-adj.)
- $238000.23 · Feb 2013
- All-time low (split-adj.)
- $0.20 · Oct 2024
- Return since IPO
- -100.0%
- Beta
- 0.81
- Book value / share
- -$4.11
- Price / book
- -1.53
Kintara Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | — | -$8.5M | — |
| FY2023 | $0.00 | -$14.6M | -$9.49 |
| FY2022 | $0.00 | -$22.6M | -$25.50 |
| FY2021 | $0.00 | -$38.3M | -$39.00 |
| FY2020 | $0.00 | -$10.1M | -$32.71 |
Last five fiscal years reported before the delisting; fiscal year ending June. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kintara Therapeutics Inc
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Kintara Therapeutics stock FAQ
What happened to Kintara Therapeutics stock?
Kintara Therapeutics stock was delisted from the Nasdaq. Its final close was $6.30 on October 18, 2024.
Is KTRA stock still trading?
No. KTRA was delisted from the Nasdaq in October 2024 and no longer trades on a U.S. exchange.
What was the last price of KTRA stock?
KTRA closed at $6.30 on its final trading day, October 18, 2024, for a market value of about $11.99M.
What were Kintara Therapeutics's revenue and earnings in its last full fiscal year?
Kintara Therapeutics reported revenue of — and net income of -$8.5M in fiscal 2024, its last full year as a public company.
When did Kintara Therapeutics go public?
Kintara Therapeutics Inc stock began trading on February 22, 2013.